CD8A and cervical cancer: Someya et al. analyzed TME immunity in cervical cancer patients treated with CRT and found that inflamed-type tumors (>30 CD8+ T cells/HPF in tumors) and excluded-type tumors (>30 CD8+ T cells/HPF in stroma but not in tumors) were associated with a better 5-year disease-specific survival (DSS) than cold-type tumors with poor CD8+ T cell infiltration (p < 0.001; 5-year DSS; 60.3% vs. 72.3% vs. 0%, respectively) [17].